1
|
Núñez Alonso D, Pérez-Torralba M, Claramunt RM, Torralba MC, Delgado-Martínez P, Alkorta I, Elguero J, Roussel C. Regiospecific Synthesis and Structural Studies of 3,5-Dihydro-4 H-pyrido[2,3- b][1,4]diazepin-4-ones and Comparison with 1,3-Dihydro-2 H-benzo[ b][1,4]diazepin-2-ones. ACS OMEGA 2020; 5:25408-25422. [PMID: 33043221 PMCID: PMC7542844 DOI: 10.1021/acsomega.0c03843] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/10/2020] [Accepted: 09/10/2020] [Indexed: 05/12/2023]
Abstract
Nine 3,5-dihydro-4H-pyrido[2,3-b][1,4]diazepin-4-ones (17-25), some of which contain fluoro-substituents, have been regiospecifically prepared by reaction of 2,3-diaminopyridines with ethyl aroylacetates. In two cases, open intermediates have been isolated and these are related to the reaction pathway. The X-ray crystal structure of 1-methyl-4-phenyl-3,5-dihydro-4H-pyrido[2,3-b][1,4]diazepin-4-one (23) has been solved (formula, C15H13N3O; crystal system, monoclinic; space group, C2/c). This is an asymmetric unit constituted by a single nonplanar molecule and its conformational enantiomer due to the presence of the seven-membered diazepin-2-one moiety, which introduces a certain degree of torsion in the adjacent pyridine ring. The 1H, 13C, 15N, and 19F NMR spectra were obtained and the chemical shifts, together with those of the previously published 1,3-dihydro-2H-benzo[b][1,4]diazepin-2-ones (1-16), i.e., a total of 544 values, were successfully compared with the chemical shifts calculated at the gauge invariant atomic orbital (GIAO)/Becke, three-parameter, Lee-Yang-Parr (B3LYP)/6-311++G(d,p) level. The seven-membered ring inversion barrier in 5-benzyl-2-phenyl-3,5-dihydro-4H-pyrido[2,3-b][1,4]diazepin-4-one (25) was determined and, in conjunction with the data from the literature, compared with the B3LYP/6-311++G(d,p) computed values. This allowed the determination of several structural effects. The rotation about the exocyclic N1-CR bond was also calculated and its dynamic properties were discussed.
Collapse
Affiliation(s)
- David Núñez Alonso
- Departamento
de Química Orgánica y Bio-Orgánica, Facultad
de Ciencias, UNED, Paseo Senda del Rey, 9, E-28040 Madrid, Spain
| | - Marta Pérez-Torralba
- Departamento
de Química Orgánica y Bio-Orgánica, Facultad
de Ciencias, UNED, Paseo Senda del Rey, 9, E-28040 Madrid, Spain
| | - Rosa M. Claramunt
- Departamento
de Química Orgánica y Bio-Orgánica, Facultad
de Ciencias, UNED, Paseo Senda del Rey, 9, E-28040 Madrid, Spain
| | - M. Carmen Torralba
- Departamento
de Química Inorgánica, Facultad de Ciencias Químicas, UCM, Avda. Complutense s/n, E-28040 Madrid, Spain
| | - Patricia Delgado-Martínez
- Unidad
de Difracción de Rayos X−CAI Técnicas Físicas
y Químicas, Facultad de Ciencias Químicas, UCM, Avda. Complutense s/n, E-28040 Madrid, Spain
| | - Ibon Alkorta
- Instituto
de Química Médica, CSIC, Juan de la Cierva, 3, E-28006 Madrid, Spain
| | - José Elguero
- Instituto
de Química Médica, CSIC, Juan de la Cierva, 3, E-28006 Madrid, Spain
| | - Christian Roussel
- Aix-Marseille
Univ., CNRS, Centrale Marseille, iSm2, 13397 Marseille, France
| |
Collapse
|
2
|
De Clercq E. Yet another ten stories on antiviral drug discovery (part D): paradigms, paradoxes, and paraductions. Med Res Rev 2010; 30:667-707. [PMID: 19626594 DOI: 10.1002/med.20173] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
This review article presents the fourth part (part D) in the series of stories on antiviral drug discovery. The stories told in part D focus on: (i) the cyclotriazadisulfonamide compounds; (ii) the {5-[(4-bromophenylmethyl]-2-phenyl-5H-imidazo[4,5-c]pyridine} compounds; (iii) (1H,3H-thiazolo[3,4-a]benzimidazole) derivatives; (iv) T-705 (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) and (v) its structurally closely related analogue pyrazine 2-carboxamide (pyrazinamide); (vi) new strategies for the treatment of hemorrhagic fever virus infections, including, as the most imminent, (vii) dengue fever, (viii) the veterinary use of acyclic nucleoside phosphonates; (ix) the potential (off-label) use of cidofovir in the treatment of papillomatosis, particularly RRP (recurrent respiratory papillomatosis); and (x) finally, the prophylactic use of tenofovir to prevent HIV infections.
Collapse
Affiliation(s)
- Erik De Clercq
- Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium.
| |
Collapse
|